Media headlines about Atara Biotherapeutics (NASDAQ:ATRA) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Atara Biotherapeutics earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 44.6461855588919 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Atara Biotherapeutics (NASDAQ ATRA) traded down 2.31% during trading on Thursday, hitting $14.80. The stock had a trading volume of 251,935 shares. The firm’s 50-day moving average price is $15.51 and its 200-day moving average price is $15.46. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $23.00. The stock’s market cap is $452.27 million.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). On average, equities research analysts predict that Atara Biotherapeutics will post ($3.90) earnings per share for the current fiscal year.
ATRA has been the subject of several research reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, August 31st. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $20.00 price objective on shares of Atara Biotherapeutics in a report on Friday, October 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a report on Monday, September 11th. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Finally, Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective for the company in a report on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $24.40.
TRADEMARK VIOLATION WARNING: “Atara Biotherapeutics (ATRA) Receives News Impact Score of 0.24” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thestockobserver.com/2017/10/12/atara-biotherapeutics-atra-receives-news-impact-score-of-0-24.html.
In other news, CEO Isaac E. Ciechanover sold 4,400 shares of the stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $15.54, for a total value of $68,376.00. Following the completion of the sale, the chief executive officer now owns 737,767 shares in the company, valued at $11,464,899.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 2,800 shares of the stock in a transaction on Monday, July 24th. The shares were sold at an average price of $16.94, for a total value of $47,432.00. Following the completion of the sale, the chief executive officer now owns 731,859 shares of the company’s stock, valued at approximately $12,397,691.46. The disclosure for this sale can be found here. Insiders have sold a total of 53,909 shares of company stock valued at $810,518 in the last quarter. Insiders own 16.20% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.